4//SEC Filing
Cohen Fred E 4
Accession 0000950170-24-015473
CIK 0001994702other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 7:03 PM ET
Size
12.2 KB
Accession
0000950170-24-015473
Insider Transaction Report
Form 4
Cohen Fred E
Director10% Owner
Transactions
- Conversion
Common Stock
2024-02-12+4,523,924→ 4,523,924 total(indirect: See Footnote) - Conversion
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12−4,401,771→ 0 total(indirect: See Footnote)→ Common Stock (967,188 underlying) - Conversion
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12−8,830,901→ 0 total(indirect: See Footnote)→ Common Stock (1,940,388 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−7,356,162→ 0 total(indirect: See Footnote)→ Common Stock (1,616,348 underlying)
Footnotes (3)
- [F1]Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
- [F2]Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.
- [F3]The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
Documents
Issuer
Kyverna Therapeutics, Inc.
CIK 0001994702
Entity typeother
Related Parties
1- filerCIK 0001339358
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 7:03 PM ET
- Size
- 12.2 KB